Log in
Enquire now
‌

US Patent 10968276 Optimized anti-CD3 variable regions

Patent 10968276 was granted and assigned to Xencor on April, 2021 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent

Patent attributes

Patent Applicant
Xencor
Xencor
Current Assignee
Xencor
Xencor
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
10968276
Patent Inventor Names
Gregory Moore0
John Desjarlais0
Matthew Bernett0
Rumana Rashid0
Date of Patent
April 6, 2021
Patent Application Number
14200652
Date Filed
March 7, 2014
Patent Citations
‌
US Patent 10227410 Heterodimeric antibodies that bind CD3 and PSMA
Patent Citations Received
‌
US Patent 12058986 Method for generating a genetically modified pig with inactivated porcine endogenous retrovirus (PERV) elements
0
‌
US Patent 11952421 Bispecific antibodies against CD3EPSILON and ROR1
0
0
Patent Primary Examiner
‌
Sean E Aeder
Patent abstract

The present invention is directed to optimized anti-CD3 variable sequences for use in a variety of bispecific formats, including those that utilize scFv components. The invention further relates to nucleic acids encoding for the polypeptide, to vectors comprising the same and to host cells comprising the vector. In another aspect, the invention provides for a pharmaceutical composition comprising the mentioned polypeptide and medical uses of the polypeptide.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 10968276 Optimized anti-CD3 variable regions

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.